

2022 Life Science Consulting Sector

Market Trends, Dynamics & Opportunities



Reach the Right Outcome



Increasing Demand For Industry-Specific Expertise



Increasingly Complex Regulatory & Reimbursement Landscape

- New regulations require increased price transparency
- State & federal entities enforce periodic, detailed pricing studies for healthcare/life sciences companies
- Payors, CROs & strategics seek to broaden in-house capabilities via niche acquisitions

Digital Revolution Upending Life Sciences Market Norms


- Connected devices & digital assets increase demand for sophisticated IT know-how
- Tech-focused companies seeking to enter life sciences market require nuanced strategic guidance
- Plethora of novel digital technologies drives heightened competition spurring outsized need for goto-market/market access strategies

Value-based Care & Personalized Solution Challenges

- Precision medicine requires enhanced data analytics & patient reporting
- Remote Patient/Therapeutic Monitoring (RPM/RTM) companies require considerable health economic analysis
- Personalized care solutions struggle to substantiate additional costs & necessitate sophisticated value communication materials

Regulatory, Reimbursement & Technology Advances Sparks Outsized Consulting Demand

Differentiated Expertise & Client Base Drives Transaction Value




Depth Of Expertise & Industry Relationships Fuel Transaction Premiums

UTCOME



High Value Biopharma Assets Require Careful Strategic Planning




Growing Innovation Promotes Competition; External Resources Utilized For Sector-Specific Expertise

Source: AP News, Research & Markets, Beroe, Inc., Grand View Research



Digital Solutions Driving Renewed MedTech Investment



Digital Transformation Across MedTech Requires Nuanced Launch Planning & Commercialization

Source: Fortune Business Insights, SVB, S&P Global, Fierce Healthcare

OUTCOME CAPITAL | LIFE SCIENCES CONSULTING Acquirers Span Strategic & Financial Continuum








Dual Strategic & Financial Interests Broadens Consolidator Base & Drives Purchase Price Values



Thoughtful Transactional Positioning Provides Optionality



Select Transaction Considerations

- > Immediate Liquidity Needs
- > Succession Planning
- > Retained "Upside"

-) Tax Implications
- Culture / Benefits
- Retention & Earn Out

Select Transaction Options

- Strategic & Private Equity
- > Unit Divestiture
- Platform & Bolt-On Structure >
-) Growth Capital Investment
- Minority / Majority Recapitalization
 - > Merger

Optimizing Transactional Outcomes Via Bespoke Processes



Transaction Value Driven By Myriad Considerations

Operational Efficiency
 Talent & Presence

Consideration	Trending Revenue	Profitability	Worldwide Capabilities	Digitized Offering	Back Office Capacity	Long-Term Clients	Tenured Consultants	Brand Recognition
Description	Accelerating top-line revenue signifies strong demand & effective business development functions	Strong margins at the business, client & project levels confirm pricing strategy	US, EU & APAC reach sought-after by multi- national strategics	Leverage data & analytics to provide meaningful insights & support client growth	High-quality support for senior management & consultants ensures successful client outcomes.	Establish master service provider contracts for potential recurring revenue opportunities for buyer.	Offer industry experience & sector- specific expertise for targeted solutions that encompass market dynamics.	Strong market presence & awareness allows for platform acquisition positioning
Value Impact								
Legend	gh							

Thoughtful Market Alignment, Transaction Preparation & Positioning Yields Maximized Shareholder Value



Financial Sponsors Seek Opportunity To Create Value



Outcome Capital Acted as Strategic & Financial Advisor on Transaction

Private Equity Groups Assign Premium Value To Differentiated Life Sciences Services



Transformative Transactions Alter Industry Dynamics

IPERION [®]		5/1/2021	Undisclosed	Life sciences consultancy providing regulatory information management services to increase interoperability, data consistency & regulatory compliance.	
Target	Buyer	Date		Target Description	
KANTAR HEALTH	E Cerner	4/1/2021	\$375	Consulting & research group offering commercial planning, medical affairs & data analytics services for companies in the life sciences sector.	
Target	Buyer	Date	Size	Target Description	
	> PHARMALEX	3/3/2021	Undisclosed	Global consulting firm providing strategic product development & regulatory support to companies in the biopharma sector.	
Target Buyer		Date	Size	Target Description	
putnam associates INSIGHT. CLARITY. STRATEGY.	UDG Healthcare plc	5/22/2019	\$89 Million	Strategic management consultancy focused on product commercialization services exclusively for biopharma, diagnostics & medical device clients.	
Target	Buyer	Date	Size	Target Description	

Previous Acquisitions Validate Demand For Expanded Service Offerings & Enhanced Market Position

Consulting Case Study: Boston Healthcare Associates, Inc.





STRATEGIC & FINANCIAL ADVISOR

Business Description

Industry Life Sciences / Healthcare Services

Vertical

Life Sciences Consulting

Offerings

Strategy consulting services tailored to biopharma, medical device, diagnostics & digital health sectors

Differentiation

Multi-disciplinary market access approach & broad payor network unlocks value based on clinical evidence, policy frameworks, reimbursement coding & health economics Transaction Challenges

Status

With a strong track record, numerous bluechip clients & premier consultants, BHA reached an inflection point & owners sought a partner offering a growth platform

Market Dynamics

Heavy consolidation underway in life sciences consulting industry as large strategics, CROs & private equity compete for portfolio enhancement

Challenges

As a family business transition to a new generation, BHA sought to maximize both short liquidity & long-term value creation



The Outcome Way

Strategic Insight

Outcome leveraged BHA's differentiated subject matter expertise to emphasize their value in a dynamic & complex reimbursement environment

Exit Strategy

Outcome analyzed industry demand & capital market trends to identify potential acquirers across the consulting, CRO & private equity universes

Process

Outcome drove a competitive process by identifying buyer-specific synergies to demonstrate BHA's unique value-add across a broad buyer universe







Consulting Case Study: Boston Healthcare Associates, Inc.



As a dedicated life sciences investment banking group, Outcome leveraged their industry knowledge in positioning BHA in the market and deftly communicated the value we offer our clients to our transaction partner. Their ability to execute alone was worth their value considering the volume of work they took on, but as a CEO it was their patient demeanor balanced by their tenacious attitude that I will remember. By the end of the transaction, I was thankful for each member of our deal team at Outcome Capital and the value they offered.

Joseph Ferrara CEO, Boston Healthcare Associates (acquired by Veranex via Summit Partners)

I knew Outcome by reputation, and they were the only group I felt comfortable engaging with. What they provided exceeded my family's expectations not only in value, but also in their conduct and earnestness. It was a pleasure doing business with Outcome Capital.

> Andrew Ferrara Chairman, Boston Healthcare Associates (acquired by Veranex via Summit Partners)

Outcome Effectively Communicated Strategic & Financial Value Of BHA Resulting In High-Value Exit



External Dynamics Drive Prosperous M&A Market

Macroeconomic Outlook						
Financial Implications Shift Focus To Strategic Investments/Acquisitions						
 Interest rates at 50-year low, reducing cost of capital & overall risk associated with M&A Stock market viewed as overvalued; investor skepticism drives strategics to long-term strategic investments as they seek new growth story to deliver to Wall Street 						
M&A & Capital Markets Outlook						
Market Conditions Create Favorable Transaction Environment						
 Strategic buyers looking to capitalize on inorganic growth opportunities to diversify capabilities & fortify market position Financial sponsors adopting platform acquisition strategy seek foundational companies as targets COVID strengthened cash positions across strategics & financial sponsors, promoting investment activity as use of funds 						
Growth Outlook						
Q4/2021 Provides Prime Opportunity For Successful Transaction						
 30-45 days required for appropriate strategic positioning to maximize probability of successful transaction Process launch in Q1/2022; aligns with financial planning & budgeting timelines for most partners End of year financials available; simplifies initial diligence for streamlined process and maximizes value Timing leverages favorable macroeconomic & capital market dynamics Prolonging exit exposes target to uncertainty of corporate tax rate, imminent increase in interest rates & impact of systematic market risk (i.e., COVID, international relations, etc.) 						

OUTCOME CAPITAL | LIFE SCIENCES SERVICES Life Science Consulting Transaction Team






Arnold Freedman

- >25 years operational and life sciences investment banking experience
- Expertise in M&A transactions and private placements of debt and equity
- Extensive financing and restructuring experience advising clients on corporate structure and operations
- Previously IBCS, Rustel, Boston Equity Advisors



Oded Ben-Joseph, PhD

- >20 years experience in life sciences; unique combination of executive, scientific and transactional expertise
- Specializes in aligning companies with sector dynamics and capital markets, capital-efficiency and value creation
- Previously Ester Neuroscience, Excel Medical, Oxford Bioscience Partners, XableCath



- 10 years operational and financial experience
- Medtech, diagnostics, biopharma & services transactional experience
- Specializes in value communication; strategic positioning; financial analysis
- Sought-after panelist, moderator & board member for Life Science trade groups



Nicholas Frame, PhD

- Extensive life sciences strategy & research experience
- Broad exposure/knowledge of novel and cutting-edge life sciences innovations
- Seasoned market expertise traversing financial/scientific dynamics underpinning product/market fit strategies



Elena Bonetti

- Facilitates in-depth public/private capital market research across verticals
- Identifies/analyzes key M&A value drivers, trends and deal structures
- Experienced transactional specialist managing organizational, administrative and execution-related activities



99 High Street Suite 2900 Boston, MA 02110 (703) 225-1500

www.outcomecapital.com

Reach the *Right Outcome*